G-17

Dosage for Ficus Carica Flower Bud is highly individualized and depends entirely on the clinical objective (diagnosis vs. treatment) and the patient's level of sensitivity.

Diagnostic Dosing

• Skin Prick Test (SPT): A single drop of the 1:10 or 1:20 w/v extract is applied to the skin (usually the forearm or back), and the skin is pricked through the drop. A positive control (histamine) and negative control (saline/glycerin) must be used concurrently.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a dose of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) may be injected intradermally to form a 2-3 mm bleb.

Immunotherapy Dosing (If Applicable)

• Initial Phase (Build-up): Dosing typically begins at a very low concentration (e.g., 0.05 mL of a 1:100,000 w/v dilution) and is increased weekly or bi-weekly as tolerated by the patient.
• Maintenance Phase: Once the target dose is reached (often 0.5 mL of a 1:100 or 1:10 w/v solution), the interval between injections is increased to every 2-4 weeks.

Ficus Carica Flower Bud extract may be used in children, but the procedure must be performed with extreme caution.

• Diagnostic Use: Dosage volumes for skin testing in children are generally the same as in adults, though the number of tests performed in one session may be limited to minimize discomfort and the risk of a systemic reaction.
• Safety: The safety and efficacy of immunotherapy using non-standardized food extracts in infants under the age of 2 have not been established. Most clinicians defer immunotherapy until the child is old enough to communicate symptoms of an impending systemic reaction.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the systemic load of the protein extract is extremely low. However, the patient's overall health status should be considered before performing diagnostic tests that could trigger systemic stress.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of these allergenic proteins occurs via general proteolytic pathways rather than hepatic enzyme systems.

Elderly Patients

Elderly patients may have reduced skin reactivity (diminished wheal and flare response). Healthcare providers may need to interpret skin test results more conservatively. Additionally, the presence of underlying cardiovascular disease in the elderly increases the risk if a systemic reaction occurs.

Ficus Carica Flower Bud extract is never for self-administration. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

• Preparation: The skin site should be cleaned with isopropyl alcohol and allowed to dry.
• Administration: For SPT, use a sterile lancet. For intradermal or immunotherapy, use a tuberculin syringe with a 26-27 gauge needle.
• Storage: Store the extract in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard if the solution becomes cloudy or shows precipitation.
• Observation: Patients must remain in the clinic for at least 30 minutes following administration to monitor for signs of anaphylaxis.

In the context of immunotherapy, if a maintenance dose is missed:

• Less than 1 week late: Administer the usual dose.
• 1-2 weeks late: The dose may need to be reduced by 25-50% to ensure safety.
• More than 4 weeks late: The build-up process may need to be restarted at a much lower concentration. Consult the prescribing allergist's specific protocol.

An overdose of Ficus Carica Flower Bud extract (either too high a concentration or too large a volume) can lead to a severe systemic allergic reaction.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, shortness of breath, or a drop in blood pressure (shock).
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3 mg for adults, 0.15 mg for children) is the first-line treatment. Oxygen, intravenous fluids, and antihistamines should be administered as secondary measures.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Side effects associated with Ficus Carica Flower Bud are most frequently localized to the site of administration. These are expected immunological responses rather than adverse drug reactions in the traditional sense.

• Localized Pruritus (Itching): Intense itching at the site of the skin test or injection is very common and typically begins within minutes.
• Erythema (Redness): A red 'flare' around the test site, caused by localized vasodilation.
• Wheal Formation: A raised, pale, or skin-colored swelling (hive) at the test site. This typically peaks at 15-20 minutes and resolves within 1-2 hours.
• Local Induration: A hardening of the tissue at the injection site that may last for 24-48 hours following immunotherapy.

• Large Local Reactions (LLR): Swelling that exceeds 10 cm in diameter at the site of an immunotherapy injection. This may be accompanied by warmth and tenderness.
• Fatigue: Some patients report a general sense of tiredness or 'malaise' for several hours after receiving allergenic extracts.
• Nasal Congestion: Mild sneezing or a runny nose may occur as part of a minor systemic response.

• Generalized Urticaria: Hives appearing on parts of the body distant from the injection site.
• Angioedema: Deep tissue swelling, most commonly affecting the lips, eyelids, or extremities.
• Gastrointestinal Distress: Nausea, abdominal cramping, or diarrhea, which can be early signs of a systemic allergic reaction.

> Warning: Stop taking Ficus Carica Flower Bud and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is the most serious risk. It is a life-threatening, multi-system allergic reaction. Symptoms include a sudden feeling of doom, rapid pulse, and dizziness.
• Laryngeal Edema: Swelling of the throat or larynx that causes difficulty swallowing or a 'tightness' in the throat.
• Bronchospasm: Sudden constriction of the airways causing wheezing, chest tightness, and severe difficulty breathing.
• Hypotension: A dangerous drop in blood pressure that can lead to fainting, loss of consciousness, or cardiac arrest.
• Cyanosis: A bluish tint to the lips or fingernails, indicating insufficient oxygen in the blood.

Because Ficus Carica Flower Bud is used intermittently for diagnosis or as part of a structured immunotherapy program, long-term side effects are rare. However, some patients undergoing multi-year immunotherapy may develop:

• Persistent Subcutaneous Nodules: Small, firm lumps at the injection sites that can take months to resolve.
• Shift in Sensitivity: In rare cases, immunotherapy can inadvertently increase sensitivity to the allergen if the dosing schedule is not managed correctly.

While Ficus Carica Flower Bud is a non-standardized extract, it falls under the general class of allergenic extracts which carry significant FDA-mandated safety warnings.

• Risk of Systemic Reactions: All allergenic extracts have the potential to cause severe, life-threatening systemic reactions, including anaphylaxis.
• Supervision Requirement: These products must only be administered in settings where clinicians are trained to recognize and treat anaphylaxis and where emergency equipment (including epinephrine) is immediately available.
• Patient Stability: Patients with unstable asthma are at a significantly higher risk for fatal reactions and must be stabilized before testing or treatment.

Report any unusual symptoms to your healthcare provider.

Ficus Carica Flower Bud extract is a potent biological substance that interacts directly with the immune system. It is not a standard medication and carries unique risks related to hypersensitivity. Patients must provide a complete medical history, specifically focusing on previous allergic reactions to figs, latex, or other fruits, before this extract is used.

No specific FDA black box warning exists solely for 'Ficus Carica Flower Bud' as an individual entity, but it is covered under the class-wide black box warning for Allergenic Extracts. This warning emphasizes that these products can cause severe anaphylactic shock. Patients must be observed for at least 30 minutes after any administration. Those with high levels of sensitivity or those receiving 'rush' immunotherapy protocols are at the greatest risk.

• Anaphylaxis Risk: The primary concern is a systemic IgE-mediated reaction. This can occur even if previous tests were well-tolerated.
• Asthma Status: Patients with symptomatic or poorly controlled asthma should not undergo skin testing or receive immunotherapy with Ficus Carica Flower Bud, as they are at a much higher risk for severe bronchospasm during a systemic reaction.
• Cardiovascular Compromise: Patients with significant heart disease may not be able to tolerate the physiological stress of a systemic reaction or the effects of the epinephrine required to treat it.
• Latex Cross-Reactivity: Because of the 'Ficus-latex syndrome,' patients with a known latex allergy must be monitored with extreme caution, as they may have a much lower threshold for a reaction to fig proteins.

• Pre-administration Assessment: Before each dose of immunotherapy, the clinician must check for any current illness (like a cold or flu) or an increase in asthma symptoms.
• Post-administration Observation: A mandatory 30-minute wait period in the clinic is standard.
• Peak Flow Monitoring: For patients with a history of asthma, a peak flow meter may be used before and after administration to ensure lung function is stable.
• Skin Site Inspection: The site of administration must be checked for the size of the wheal and flare or any delayed-phase swelling.

Ficus Carica Flower Bud generally does not affect the ability to drive or operate machinery. However, if a patient experiences a systemic reaction, dizziness, or receives antihistamines or epinephrine as treatment, they should not drive until they are fully recovered and cleared by a physician.

Alcohol consumption should be avoided on the day of skin testing or immunotherapy. Alcohol can increase peripheral vasodilation and potentially accelerate the absorption of the allergen or mask the early symptoms of a systemic reaction.

If a patient experiences a severe systemic reaction, the use of Ficus Carica Flower Bud should be discontinued immediately. A thorough risk-benefit analysis must be performed before considering a restart at a much lower concentration.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ficus Carica Flower Bud.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are absolutely contraindicated in patients receiving allergenic extracts. Beta-blockers can make a systemic allergic reaction (anaphylaxis) much more severe and, crucially, can render the emergency treatment (epinephrine) ineffective by blocking the beta-adrenergic receptors.
• Unstable Asthma Medications: If a patient requires high-dose rescue inhalers daily, the use of allergenic extracts is contraindicated until the asthma is controlled.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These may increase the risk of severe or prolonged anaphylactic reactions and have been associated with a higher incidence of angioedema.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine if it needs to be administered for a reaction, potentially leading to a hypertensive crisis.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular sensitivity to epinephrine.

• Antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine): These medications must be discontinued 3 to 7 days before diagnostic skin testing. They block the H1 receptors, which prevents the 'wheal and flare' reaction, leading to a false-negative result. They do not, however, prevent the more dangerous systemic components of anaphylaxis.
• H2 Blockers (e.g., Famotidine): These can also mildly suppress skin test reactivity and should ideally be discontinued before testing.
• Systemic Corticosteroids: Long-term use of oral steroids (like prednisone) can suppress the skin's inflammatory response to allergens, though short-term or low-dose use may have a negligible effect.

• Cross-Reactive Foods: Patients sensitive to Ficus Carica Flower Bud may also react to other members of the Moraceae family (mulberries, breadfruit) or foods containing similar proteases (kiwi, papaya, pineapple). Consuming these foods shortly before or after testing may exacerbate a reaction.
• High-Fat Meals: There is no direct interaction, but heavy meals may complicate the management of gastrointestinal symptoms if a systemic reaction occurs.

• St. John's Wort: May theoretically interact with medications used to treat anaphylaxis.
• Feverfew/Ginkgo: These have mild anti-platelet effects but are generally not a major concern unless the patient is prone to bruising at the injection site.

• Skin Prick Tests: As noted, the extract is the reagent for this test. The presence of interfering drugs (antihistamines) is the primary concern.
• Serum IgE Tests: Ficus Carica Flower Bud administration does not typically interfere with the accuracy of blood-based allergy tests (like ImmunoCAP), though successful immunotherapy will eventually lead to an increase in IgG4 antibodies and a potential decrease in IgE over several years.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Ficus Carica Flower Bud must NEVER be used in the following circumstances:

• Previous Severe Anaphylaxis to Fig: If a patient has a history of life-threatening reactions to very small amounts of fig, the risk of skin testing or immunotherapy may outweigh the diagnostic benefit.
• Uncontrolled or Severe Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values are at an unacceptable risk for fatal bronchospasm.
• Beta-Blocker Therapy: As previously mentioned, the inability to respond to epinephrine is a life-threatening contraindication.
• Acute Infection: Testing should not be performed while a patient has a fever or active viral/bacterial infection, as the immune system is already in a heightened state.

Conditions requiring careful risk-benefit analysis include:

• Pregnancy: While not a direct teratogen, the risk of maternal anaphylaxis and subsequent fetal hypoxia makes starting new immunotherapy or performing intensive skin testing generally inadvisable during pregnancy.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to allergenic extracts.
• Severe Atopic Dermatitis: If the skin is extensively involved with eczema, there may be no 'clear' skin available for accurate testing, and the risk of a flare-up is higher.

Patients should be evaluated for cross-sensitivity to:

• Natural Rubber Latex: Due to shared proteins like Hev b 6.02 and Ficus proteases.
• Other Ficus Species: Including Ficus elastica (rubber plant) and Ficus benjamina (weeping fig).
• Papain/Bromelain: Patients with allergies to these enzymes may also react to the ficin in Ficus Carica Flower Bud.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ficus Carica Flower Bud.

Ficus Carica Flower Bud is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. The primary clinical concern is not the extract itself, but the potential for a systemic allergic reaction in the mother. Anaphylaxis during pregnancy can lead to maternal hypotension, which causes uterine hypoperfusion and fetal hypoxia (lack of oxygen), potentially resulting in fetal neurological damage or death. Therefore, starting immunotherapy or performing diagnostic skin tests is generally deferred until postpartum. If a woman is already on a stable maintenance dose of immunotherapy and becomes pregnant, the clinician may choose to continue the treatment but will typically not increase the dose.

It is not known whether the allergenic proteins in Ficus Carica Flower Bud are excreted in human milk. Because these are large proteins that are likely degraded in the maternal gastrointestinal tract if swallowed, or localized in the skin/lymphatics if injected, the risk to the nursing infant is considered extremely low. However, the clinician should consider the risk-benefit ratio. There is no evidence that immunotherapy during breastfeeding sensitizes the infant to figs.

Skin testing with Ficus Carica Flower Bud is considered safe and effective in children, including infants, when performed by a specialist. However, the 'wheal' response may be smaller in infants under 6 months of age. For immunotherapy, the safety and efficacy have been established primarily in children aged 5 and older. The primary challenge in younger children is their inability to clearly communicate the early, subtle symptoms of a systemic reaction (such as an itchy throat or a sense of 'doom').

Clinical studies of allergenic extracts generally do not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In elderly patients, the skin's reactivity to histamine and allergens decreases with age, which may lead to smaller wheal diameters and potential false negatives. Furthermore, the elderly are more likely to have co-morbidities like coronary artery disease or COPD, which increase the danger of a systemic reaction.

There are no specific guidelines for Ficus Carica Flower Bud use in renal impairment. Since the extract is a protein-based biologic administered in minute quantities, it does not require the same renal clearance mechanisms as small-molecule drugs. However, patients with end-stage renal disease (ESRD) may have altered immune profiles and should be monitored closely.

No dosage adjustments are required for patients with hepatic impairment. The liver is not the primary organ for the clearance of these allergenic proteins, which are instead broken down by ubiquitous proteases.

> Important: Special populations require individualized medical assessment.

Ficus Carica Flower Bud extract acts as an exogenous antigen. Its primary molecular targets are the allergen-specific IgE antibodies bound to the FcεRI receptors on the surface of mast cells and basophils. The extract contains multiple protein allergens, the most significant being Fic c 1 and ficin. When these proteins cross-link two adjacent IgE molecules, it triggers an influx of calcium ions into the mast cell. This leads to the fusion of intracellular granules with the cell membrane and the subsequent release of pre-formed mediators like histamine and heparin, as well as the rapid synthesis of newly formed mediators like leukotrienes (LTC4, LTD4) and prostaglandins (PGD2). In immunotherapy, the mechanism shifts toward inducing immune tolerance by promoting the production of IgG4 'blocking' antibodies and shifting the T-cell response from a Th2 (pro-allergic) to a Th1 or Treg (regulatory) profile.

• Onset of Effect: For diagnostic skin testing, the pharmacodynamic effect (wheal and flare) begins within 5 minutes and peaks at 15-20 minutes.
• Duration of Effect: The localized skin reaction typically fades within 1-2 hours. In immunotherapy, the pharmacodynamic effect is cumulative and may take 6-12 months of regular injections to significantly reduce clinical allergy symptoms.
• Tolerance: Unlike many drugs, 'tolerance' in this context is the desired therapeutic outcome—the immune system becomes less reactive to the allergen over time.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Local Skin Test); Slow/Variable (SCIT) |

| Protein Binding | Primarily binds to IgE and IgG antibodies |

| Half-life | Proteins degraded within hours to days |

| Tmax | 15-20 minutes (for local skin reaction) |

| Metabolism | Proteolytic degradation (non-CYP) |

| Excretion | Renal (as peptide fragments) |

• Molecular Formula: N/A (Complex mixture of proteins, glycoproteins, and polysaccharides).
• Molecular Weight: Ranges from 10 kDa to over 120 kDa (for major allergens like Fic c 1).
• Solubility: Soluble in aqueous buffers and 50% glycerin solutions.
• Structure: The extract consists of various globular proteins and enzymes (like the cysteine protease ficin) derived from the Ficus carica inflorescence.

Ficus Carica Flower Bud is classified as a Non-Standardized Food Allergenic Extract. It is grouped with other plant-derived extracts used for diagnostic and therapeutic purposes in allergy and immunology. It is distinct from 'standardized' extracts like those for Grass Pollen or Cat Hair, which have federally mandated potency units.